DHA (Docosahexaenoic Acid) is the main Omega Fatty Acid in brain and eyes. DHA is a nutrient found in algae, fish, and breast milk. Other studies suggest that DHA is a key part of fish oil that protects the brain.
Background and Significance
This study of the clinical effects of DHA is being done because there is evidence that DHA can modify AD-specific pathology.
What is the main objective of this study?
The main objective of this study is to find out whether daily use of DHA is able to stop or slow the progression of Alzheimer's disease.
How will the study be conducted?
Your participation will involve approximately 8 clinic visits during a period of 18 months. This is a double-blind, placebo-controlled study. This means that if you choose to enroll, it will be determined by chance whether you will receive the active study drug (DHA) or placebo (a pill without any DHA). Neither the participants nor the study doctor will whether or not you are receiving the active drug or placebo. In the event of a serious side effect, however, this information can be determine immediately.
How many patients will be participating in the study?
A total of 400 participants will be recruited for the study with at least 12 participants from USC.
Who is eligible to participate in this study?
The following are the eligibility criteria for this study:
Diagnosis of probable AD, with MMSE score of 14-26 inclusive.
Taking less than 200 mg of DHA two months before screening (DHA is normally found in the diet, but not in large amounts).
How can I enroll in this study?
This study is currently enrolling volunteers. If interested, please contact:
University of Southern California Keck School of Medicine